Kala Bio (KALA) Accumulated Expenses (2016 - 2026)
Kala Bio (KALA) posted Accumulated Expenses of $513000.0 for Q1 2026, down 65.98% sequentially from $1.5 million in Q4 2025, and down 44.84% YoY from $930000.0 in Q1 2025.
Kala Bio (KALA) Accumulated Expenses (2016 - 2026) Analysis & Trends
Kala Bio has reported Accumulated Expenses for 11 years, with the latest figure at $513000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 44.84% year-over-year to $513000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $513000.0 (down 44.84% YoY) and the FY2025 annual result came in at $1.5 million, down 69.69% from the prior year.
- Accumulated Expenses eased to $513000.0 in Q1 2026 per KALA's latest filing, from $1.5 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $25.4 million in Q3 2022 and troughed at $513000.0 in Q1 2026.
- A 5-year average of $3.9 million and a median of $2.6 million in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses jumped 928.14% in 2022, then plunged 89.03% in 2023.
- Over 5 years, Accumulated Expenses stood at $3.3 million in 2022, then decreased by 21.54% to $2.6 million in 2023, then soared by 90.18% to $5.0 million in 2024, then tumbled by 69.69% to $1.5 million in 2025, then sank by 65.98% to $513000.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $513000.0, $1.5 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 513,000.00 |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 1.51 Mn |
| Mar 31, 2025 | 930,000.00 |
| Dec 31, 2024 | 4.98 Mn |
| Sep 30, 2024 | 775,000.00 |
| Jun 30, 2024 | 723,000.00 |
| Mar 31, 2024 | 4.81 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 2.78 Mn |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 3.33 Mn |
| Sep 30, 2022 | 25.37 Mn |
| Jun 30, 2022 | 5.48 Mn |
| Mar 31, 2022 | 4.59 Mn |
| Dec 31, 2021 | 6.32 Mn |
| Sep 30, 2021 | 8.65 Mn |
| Jun 30, 2021 | 533,000.00 |